A review of the efficacy of human Q fever vaccine registered in Australia
Clayton K. Chiu A and David N. Durrheim B CA NSW Public Health Officer Training Program, NSW Department of Health
B Hunter New England Population Health, Hunter New England Area Health Service
C Corresponding author. Email: David.Durrheim@hnehealth.nsw.gov.au
NSW Public Health Bulletin 18(8) 133-136 https://doi.org/10.1071/NB07057
Published: 27 August 2007
Abstract
Background: Q fever remains an important occupational zoonosis in rural Australia. Although Q fever vaccine is recommended in high-risk occupational groups, its availability has been limited in recent years. Method: A literature review of the efficacy of the human Q fever vaccine registered in Australia was conducted. Results: Seven relevant vaccine efficacy studies were identified but no large double-blind, randomised, placebo-controlled studies have been conducted. Vaccine efficacy has ranged from 83–100% but limitations of study designs hamper a precise estimate of vaccine efficacy. Conclusion: Despite the shortcomings of efficacy studies, the Q fever vaccine available in Australia has considerable protective benefit in established high-risk environments, particularly of an occupational nature.
Acknowledgements
Data from the NSW Notifiable Diseases Database was accessed through the Health Outcomes Information and Statistics Toolkit (HOIST) system, a data access, analysis and reporting facility established and operated by the Centre for Epidemiology and Research, Population Health Division, NSW Department of Health
[1] Maurin M, Raoult D. Q fever. Clin Microbiol Rev 1999; 12 518–53.
| PubMed |
[2] Grieg JE, Patel MS, Clements MS, Taylor NK. Control strategies for Q fever based on results of pre-vaccination screening in Victoria, 1998 to 2001. Aust N Z J Public Health 2005; 29 53–7.
| PubMed |
[3]
[4] Shapiro RA, Siskind V, Schofield FD, Stallman N, Worswick DA, Marmion BP. A randomized, controlled, double-blind, cross-over, clinical trial of Q fever vaccine in selected Queensland abattoirs. Epidemiol Infect 1990; 104 267–73.
| PubMed |
[5] Gilroy N, Formica N, Beers M, Egan A, Conaty S, Marmion B. Abattoir-associated Q fever: a Q fever outbreak during a Q fever vaccination program. Aust N Z J Public Health 2001; 25 362–7.
| PubMed |
[6] Ackland JR, Worswick DA, Marmion BP. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985–1990. Med J Aust 1994; 160 704–8.
| PubMed |
[7] Marmion BP, Kyrkou M, Worswick D, Esterman A, Ormsbee RA, Wright J, Cameron S, Feery B, Collins W. Vaccine prophylaxis of abattoir-associated Q fever. Lancet 1984; 342 1411–4.
| Crossref | GoogleScholarGoogle Scholar |
[8] Marmion BP, Ormsbee RA, Kyrkou M, Wright J, Worswick DA, Izzo AA, Esterman A, Feery B, Shapiro RA. Vaccine prophylaxis of abattoir-associated Q fever: eight years’ experience in Australian abattoirs. Epidemiol Infect 1990; 104 275–87.
| PubMed |
[9] Kermode M, Yong K, Hurley S, Marmion B. An economic evaluation of increased uptake in Q fever vaccination among meat and agricultural industry workers following implementation of the National Q Fever Management Program. Aust N Z J Public Health 2003; 27 390–8.
| PubMed |
[10] Garner MG, Longbottom HM, Cannon RM, Plant AJ. A review of Q fever in Australia 1991–1994. Aust N Z J Public Health 1997; 21 722–30.
| PubMed |
